ZEALAND PHARMA
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim. Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is ... marketed globally outside the US as Lyxumia:registered: by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus:registered:) which is on track for regulatory submission in the US in December 2015 and in the European Union in Q1 2016. The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics. The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma
ZEALAND PHARMA
Industry:
Biopharma Biotechnology Health Care
Founded:
1998-01-01
Address:
Copenhagen, Hovedstaden, Denmark
Country:
Denmark
Website Url:
http://www.zealandpharma.com
Total Employee:
251+
Status:
Active
Contact:
45 88 77 36 00
Email Addresses:
[email protected]
Total Funding:
1.59 B USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Apple Mobile Web Clips Icon Google Tag Manager WordPress Google Analytics Global Site Tag Mobile Non Scaleable Content Organization Schema
Similar Organizations
Arcellx
Arcellx is a clinical-stage biotechnology company that provides patients with immune cell therapies.
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals is a biotechnology company that focuses on the development of medicine to treat diseases with a genetic origin.
Aura Biosciences
Aura Biosciences is a biotechnology company that focuses on the development of drugs by using tumor targeted pseudovirions.
Healx
Healx is an AI-powered, patient-inspired technology company, pioneering the next generation of drug discovery for rare diseases.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
ZOE Health Study
ZOE Health Study is a biotechnology research company that offers technology to unlock the secrets of the immune system.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2020-02-10 | Valeritas | Valeritas acquired by Zealand Pharma | 23 M USD |
| 2019-10-23 | Encycle Therapeutics | Encycle Therapeutics acquired by Zealand Pharma | N/A |
Investors List
European Investment Bank
European Investment Bank investment in Post-IPO Debt - Zealand Pharma
Oberland Capital
Oberland Capital investment in Post-IPO Debt - Zealand Pharma
Athyrium Capital Management LP
Athyrium Capital Management LP investment in Post-IPO Equity - Zealand Pharma
Idinvest Partners
Idinvest Partners investment in Venture Round - Zealand Pharma
Innovation Capital
Innovation Capital investment in Venture Round - Zealand Pharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2019-01-08 | Beta Bionics | Zealand Pharma investment in Series B - Beta Bionics | 63 M USD |
Key Employee Changes
Official Site Inspections
http://www.zealandpharma.com Semrush global rank: 723.14 K Semrush visits lastest month: 42.66 K
- Host name: 104.47.160.14
- IP address: 104.47.160.14
- Location: Amsterdam Netherlands
- Latitude: 52.3534
- Longitude: 4.9087
- Timezone: Europe/Amsterdam
- Postal: 1091
More informations about "Zealand Pharma"
About us - Zealand Pharma
Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to …See details»
Corporate governance - About us - Zealand Pharma
Zealand’s Corporate Governance structure includes the Annual General Meeting, the Board of Directors and Committees, Corporate Management, and the rest of the organization. Corporate management Board of DirectorsSee details»
Zealand Pharma - Wikipedia
Zealand Pharma A/S is a Danish biotechnology research company, which designs and develops peptide-based medicines, mainly focusing on metabolic diseases like diabetes and obesity. The company's head office is situated in Søborg near Copenhagen, and it has close to 200 employees. In 2018, they opened a subsidiary in the US. Zealand Pharma forms part of the Danish-Swedish life science cluster Medicon Valley. See details»
Zealand Pharma A/S - Overview, News & Similar companies
Mar 20, 2024 Explore Complete Organization Structure. Is Zealand Pharma A/S your ideal customer? Let us give you the heads up on whether it's a good time to reach out ... Phone …See details»
Zealand Pharma - Crunchbase Company Profile
Contact Email [email protected] Phone Number 45 88 77 36 00 Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines.See details»
Zealand Pharma - LinkedIn
From our start in 1998, Zealand Pharma has been dedicated to the discovery, design, and development of innovative peptide-based medicines. Now, 300+ employees and 26 years later, our purpose is ...See details»
Zealand Pharma Appoints New Chief Executive Officer, Refocuses …
Mar 30, 2022 Company announcement – No. 10 / 2022 Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines …See details»
Focused on Growing our Most Valuable Asset - Zealand Pharma
From its origins as a research organization to one that now has a global footprint, multiple clinical trials running with unique breakthrough molecules and fantastic employees. We are at a point …See details»
Zealand Pharma CEO and Key Executive Team | Craft.co
Zealand Pharma's President and Chief Executive Officer is Adam Steensberg. Other executives include David Kendall, Chief Medical Officer; Ivan Møller, Executive Vice President and Chief …See details»
Zealand Pharma Appoints New Chief Executive Officer,
Mar 30, 2022 Company announcement – No. 10 / 2022 Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines …See details»
Zealand Pharma Expands U.S. Operations, Opens New Boston Office
Jul 6, 2020 ·Commercial operations will be headquartered in Boston, as company looks to commercialize pipeline in the U.S. Copenhagen, DK and Boston, MA, U.S. July 6, 2020 – …See details»
Zealand Pharma: on Track for Potential First Product Launch
Mar 11, 2021 [email protected]. Zealand Pharma Media Relations David Rosen Argot Partners [email protected]. NOTE: Exchange rates used: 31 Dec 2020 = …See details»
Zealand Pharma: on Track for Potential First Product Launch and ...
Mar 11, 2021 Company announcement – No. 12 / 2021 Zealand Pharma: on Track for Potential First Product Launch and Establishing Commercial Operations in the United States Full Year …See details»
Our impact - About us - Zealand Pharma
We recognize the importance of operating a responsible and sustainable business and we have identified three pillars: our patients, our people, and our operationsSee details»
Zealand Pharma Announces Global License and Development
Sep 7, 2022 Company announcement – No. 38 / 2022. Agreement includes an upfront payment, development, regulatory, manufacturing and sales-based milestones of up to DKK 290 million …See details»
Investors - Zealand Pharma
3 days ago Zealand Pharma is an international biotechnology company headquartered in Denmark. We are focused on the discovery, design, and development of innovative peptide …See details»
Zealand Pharma: Significant Advancement of Clinical
Oct 3, 2022 NOTE: Exchange rates used: 31 Dec 2021 = 6.56 and 31 Dec 2020 = 6.54. About Zealand Pharma A/S . Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology …See details»
Careers - Zealand Pharma
We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. Making bonds is at the core of everything we do: discovering and developing …See details»
Zealand Pharma Announces Seven-Year, $200 Million Financing
Dec 14, 2021 Company announcement – No. 75 / 2021. Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital . Agreement includes an …See details»